Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study

The objective of this paper is to investigate the effects of liraglutide in combination with short-term continuous subcutaneous insulin infusion (CSII) therapy on glycemic control and beta cell function in patients with newly diagnosed type 2 diabetes mellitus (T2DM). Thirty-nine eligible newly diag...

Full description

Saved in:
Bibliographic Details
Main Authors: Weijian Ke, Liehua Liu, Juan Liu, Ailing Chen, Wanping Deng, Pengyuan Zhang, Xiaopei Cao, Zhihong Liao, Haipeng Xiao, Jianbin Liu, Yanbing Li
Format: Article
Language:English
Published: Wiley 2016-01-01
Series:Journal of Diabetes Research
Online Access:http://dx.doi.org/10.1155/2016/6839735
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850106299963932672
author Weijian Ke
Liehua Liu
Juan Liu
Ailing Chen
Wanping Deng
Pengyuan Zhang
Xiaopei Cao
Zhihong Liao
Haipeng Xiao
Jianbin Liu
Yanbing Li
author_facet Weijian Ke
Liehua Liu
Juan Liu
Ailing Chen
Wanping Deng
Pengyuan Zhang
Xiaopei Cao
Zhihong Liao
Haipeng Xiao
Jianbin Liu
Yanbing Li
author_sort Weijian Ke
collection DOAJ
description The objective of this paper is to investigate the effects of liraglutide in combination with short-term continuous subcutaneous insulin infusion (CSII) therapy on glycemic control and beta cell function in patients with newly diagnosed type 2 diabetes mellitus (T2DM). Thirty-nine eligible newly diagnosed T2DM patients were recruited and randomized to receive either of two therapies: short-term CSII alone (CSII alone group) or CSII in combination with liraglutide (CSII + Lira group) for 12 weeks. Blood glucose control, homeostasis model assessment (HOMA) indices, and acute insulin response (AIR) were compared between the two groups. The patients in CSII + Lira group achieved euglycemia with equivalent insulin dosage in shorter time (1 (0) versus 2 (3) days, P=0.039). HbA1c at the end of study was comparable between two groups (6.3±0.7% versus 6.0±0.5%, for CSII alone group and CSII + Lira group, resp., P=0.325). The increment of AIR was higher in CSII + Lira group (177.58 (351.57) μU·min/mL versus 58.15 (51.30) μU·min/mL, P<0.001). However, after stopping liraglutide, its effect on beta cell function disappeared completely. Liraglutide combined with short-term CSII was effective in further improving beta cell function, but the beneficial effects did not sustain after suspension of the therapy.
format Article
id doaj-art-2e837212cb694a998de18f7df766a91e
institution OA Journals
issn 2314-6745
2314-6753
language English
publishDate 2016-01-01
publisher Wiley
record_format Article
series Journal of Diabetes Research
spelling doaj-art-2e837212cb694a998de18f7df766a91e2025-08-20T02:38:51ZengWileyJournal of Diabetes Research2314-67452314-67532016-01-01201610.1155/2016/68397356839735Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot StudyWeijian Ke0Liehua Liu1Juan Liu2Ailing Chen3Wanping Deng4Pengyuan Zhang5Xiaopei Cao6Zhihong Liao7Haipeng Xiao8Jianbin Liu9Yanbing Li10Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, ChinaDepartment of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, ChinaDepartment of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, ChinaDepartment of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, ChinaDepartment of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, ChinaDepartment of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, ChinaDepartment of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, ChinaDepartment of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, ChinaDepartment of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, ChinaDepartment of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, ChinaDepartment of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, ChinaThe objective of this paper is to investigate the effects of liraglutide in combination with short-term continuous subcutaneous insulin infusion (CSII) therapy on glycemic control and beta cell function in patients with newly diagnosed type 2 diabetes mellitus (T2DM). Thirty-nine eligible newly diagnosed T2DM patients were recruited and randomized to receive either of two therapies: short-term CSII alone (CSII alone group) or CSII in combination with liraglutide (CSII + Lira group) for 12 weeks. Blood glucose control, homeostasis model assessment (HOMA) indices, and acute insulin response (AIR) were compared between the two groups. The patients in CSII + Lira group achieved euglycemia with equivalent insulin dosage in shorter time (1 (0) versus 2 (3) days, P=0.039). HbA1c at the end of study was comparable between two groups (6.3±0.7% versus 6.0±0.5%, for CSII alone group and CSII + Lira group, resp., P=0.325). The increment of AIR was higher in CSII + Lira group (177.58 (351.57) μU·min/mL versus 58.15 (51.30) μU·min/mL, P<0.001). However, after stopping liraglutide, its effect on beta cell function disappeared completely. Liraglutide combined with short-term CSII was effective in further improving beta cell function, but the beneficial effects did not sustain after suspension of the therapy.http://dx.doi.org/10.1155/2016/6839735
spellingShingle Weijian Ke
Liehua Liu
Juan Liu
Ailing Chen
Wanping Deng
Pengyuan Zhang
Xiaopei Cao
Zhihong Liao
Haipeng Xiao
Jianbin Liu
Yanbing Li
Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study
Journal of Diabetes Research
title Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study
title_full Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study
title_fullStr Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study
title_full_unstemmed Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study
title_short Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study
title_sort effects of liraglutide combined with short term continuous subcutaneous insulin infusion on glycemic control and beta cell function in patients with newly diagnosed type 2 diabetes mellitus a pilot study
url http://dx.doi.org/10.1155/2016/6839735
work_keys_str_mv AT weijianke effectsofliraglutidecombinedwithshorttermcontinuoussubcutaneousinsulininfusiononglycemiccontrolandbetacellfunctioninpatientswithnewlydiagnosedtype2diabetesmellitusapilotstudy
AT liehualiu effectsofliraglutidecombinedwithshorttermcontinuoussubcutaneousinsulininfusiononglycemiccontrolandbetacellfunctioninpatientswithnewlydiagnosedtype2diabetesmellitusapilotstudy
AT juanliu effectsofliraglutidecombinedwithshorttermcontinuoussubcutaneousinsulininfusiononglycemiccontrolandbetacellfunctioninpatientswithnewlydiagnosedtype2diabetesmellitusapilotstudy
AT ailingchen effectsofliraglutidecombinedwithshorttermcontinuoussubcutaneousinsulininfusiononglycemiccontrolandbetacellfunctioninpatientswithnewlydiagnosedtype2diabetesmellitusapilotstudy
AT wanpingdeng effectsofliraglutidecombinedwithshorttermcontinuoussubcutaneousinsulininfusiononglycemiccontrolandbetacellfunctioninpatientswithnewlydiagnosedtype2diabetesmellitusapilotstudy
AT pengyuanzhang effectsofliraglutidecombinedwithshorttermcontinuoussubcutaneousinsulininfusiononglycemiccontrolandbetacellfunctioninpatientswithnewlydiagnosedtype2diabetesmellitusapilotstudy
AT xiaopeicao effectsofliraglutidecombinedwithshorttermcontinuoussubcutaneousinsulininfusiononglycemiccontrolandbetacellfunctioninpatientswithnewlydiagnosedtype2diabetesmellitusapilotstudy
AT zhihongliao effectsofliraglutidecombinedwithshorttermcontinuoussubcutaneousinsulininfusiononglycemiccontrolandbetacellfunctioninpatientswithnewlydiagnosedtype2diabetesmellitusapilotstudy
AT haipengxiao effectsofliraglutidecombinedwithshorttermcontinuoussubcutaneousinsulininfusiononglycemiccontrolandbetacellfunctioninpatientswithnewlydiagnosedtype2diabetesmellitusapilotstudy
AT jianbinliu effectsofliraglutidecombinedwithshorttermcontinuoussubcutaneousinsulininfusiononglycemiccontrolandbetacellfunctioninpatientswithnewlydiagnosedtype2diabetesmellitusapilotstudy
AT yanbingli effectsofliraglutidecombinedwithshorttermcontinuoussubcutaneousinsulininfusiononglycemiccontrolandbetacellfunctioninpatientswithnewlydiagnosedtype2diabetesmellitusapilotstudy